Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early synovial and blood effects of infliximab in rheumatoid arthritis
NL-OMON20080Active, not recruiting
- Sponsor
- Principal investigator: Prof. Dr. P.P. Tak Academic Medical Center (AMC), Division of Clinical Immunology and Rheumatology
- Start
- Oct 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab in rheumatoid arthritis (RA) (3 cohorts), sponsored by Principal investigator: Prof. Dr. P.P. Tak Academic Medical Center (AMC), Division of Clinical Immunology and Rheumatology. Primary endpoints: Synovial tissue apoptosis within 1 or 24 hours and Peripheral blood mononuclear cell apoptosis within 1 or 24 hours. Started Oct 2003; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20080.